444 related articles for article (PubMed ID: 29153775)
1. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
[TBL] [Abstract][Full Text] [Related]
2. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K
Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
5. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
[TBL] [Abstract][Full Text] [Related]
6. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
7. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM; Berry DA; Perou CM; Singh B; Cirrincione CT; Tolaney SM; Kuzma CS; Pluard TJ; Somlo G; Port ER; Golshan M; Bellon JR; Collyar D; Hahn OM; Carey LA; Hudis CA; Winer EP
J Clin Oncol; 2015 Jan; 33(1):13-21. PubMed ID: 25092775
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
Yamasaki M; Murakami I; Nakano K; Doi M; Kitaguchi S; Kondo T; Sakurai J; Hattori N; Arita KI
Anticancer Res; 2017 Feb; 37(2):923-928. PubMed ID: 28179353
[TBL] [Abstract][Full Text] [Related]
9. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
Chan JK; Brady MF; Penson RT; Huang H; Birrer MJ; Walker JL; DiSilvestro PA; Rubin SC; Martin LP; Davidson SA; Huh WK; O'Malley DM; Boente MP; Michael H; Monk BJ
N Engl J Med; 2016 Feb; 374(8):738-48. PubMed ID: 26933849
[TBL] [Abstract][Full Text] [Related]
10. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS
J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578
[TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F
J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797
[TBL] [Abstract][Full Text] [Related]
13. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
Guarneri V; Dieci MV; Bisagni G; Boni C; Cagossi K; Puglisi F; Pecchi A; Piacentini F; Conte P
Ann Surg Oncol; 2015 Sep; 22(9):2881-7. PubMed ID: 25572687
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
Takeoka H; Yamada K; Naito Y; Matsuo N; Ishii H; Tokito T; Azuma K; Ichiki M; Hoshino T
Anticancer Res; 2018 Jun; 38(6):3779-3784. PubMed ID: 29848743
[TBL] [Abstract][Full Text] [Related]
15. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Krasner CN; Castro C; Penson RT; Roche M; Matulonis UA; Morgan MA; Drescher C; Armstrong DK; Wolfe JK; Lee H; Supko JG; Seiden M; Birrer MJ; Dizon DS
Gynecol Oncol; 2019 May; 153(2):223-229. PubMed ID: 30765148
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H
Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074
[TBL] [Abstract][Full Text] [Related]
18. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
19. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
20. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
